Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6699578 | 0.89 | TSHR (0.42) | TSHRLMNADNM1THRB | |
| Bromide SCHEMBL6700646 | 0.89 | TSHR (0.42) | TSHRLMNADNM1THRB | |
| Bromide SCHEMBL6697844 | 0.85 | TSHR (0.35) | TSHRLMNADNM1THRB | |
| SCHEMBL6661102 | 0.84 | TSHR (0.40) | TSHRLMNADNM1THRB | |
| SCHEMBL1357901 | 0.84 | TSHR (0.40) | TSHRLMNADNM1THRB | |
| SCHEMBL383130 | 0.84 | — | — | |
| Bromide SCHEMBL6701283 | 0.82 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL9350919 | 0.81 | TSHR (0.38) | TSHRLMNADNM1THRB | |
| SCHEMBL15657886 | 0.81 | TSHR (0.38) | TSHRLMNADNM1THRB | |
| Bromide SCHEMBL6704448 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774265-B2 | SALT FORMATION REACTION OF PHOSPHINE AND SECONDARY PHOSPHINE IN ALCOHOLIC SOLVENT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20040138504-A1 | BISPHOSPHONIUM SALT AND PROCESS FOR PRODUCING THE SAME | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138504-A1 | BISPHOSPHONIUM SALT AND PROCESS FOR PRODUCING THE SAME | PIP5K1B, PIP5K1A, PHOSPHO1 | TSHR 1087/4885LMNA 4245/4885DNM1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.